NO940035D0 - Kolesterolester, samt anvendelse av slike estere - Google Patents

Kolesterolester, samt anvendelse av slike estere

Info

Publication number: NO940035D0
Authority: NO; Norway
Prior art keywords: esters; well; cholesterol; fatty acid; columbinic
Prior art date: 1993-01-06

Application number

NO940035A

Other languages

English (en)

Norwegian (no)

Other versions

NO940035L (de

Inventor

David Frederick Horrobin

Original Assignee

Scotia Holdings Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-01-06

Filing date

1994-01-05

Publication date

1994-01-05

1994-01-05 Application filed by Scotia Holdings Plc filed Critical Scotia Holdings Plc

1994-01-05 Publication of NO940035D0 publication Critical patent/NO940035D0/no

1994-07-07 Publication of NO940035L publication Critical patent/NO940035L/no

Links

150000001840 cholesterol esters Chemical class 0.000 title 1
150000002148 esters Chemical class 0.000 title 1
235000014113 dietary fatty acids Nutrition 0.000 abstract 2
229930195729 fatty acid Natural products 0.000 abstract 2
239000000194 fatty acid Substances 0.000 abstract 2
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
-1 Cholesterol fatty acid esters Chemical class 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
150000007513 acids Chemical class 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 1
235000004626 essential fatty acids Nutrition 0.000 abstract 1
150000004665 fatty acids Chemical class 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Fats And Perfumes (AREA)
Cosmetics (AREA)
Optical Recording Or Reproduction (AREA)
Medicinal Preparation (AREA)

NO940035A 1993-01-06 1994-01-05 Kolesterolester, samt anvendelse av slike estere NO940035D0 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB939300125A GB9300125D0 (en)	1993-01-06	1993-01-06	Compositions containing esters of unsaturated fatty acids

Publications (2)

Publication Number	Publication Date
NO940035D0 true NO940035D0 (no)	1994-01-05
NO940035L NO940035L (de)	1994-07-07

Family

ID=10728334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO940035A NO940035D0 (no)	1993-01-06	1994-01-05	Kolesterolester, samt anvendelse av slike estere

Country Status (17)

Country	Link
US (1)	US5604216A (de)
EP (1)	EP0606012B1 (de)
JP (1)	JPH06234644A (de)
KR (1)	KR940018088A (de)
CN (1)	CN1096197A (de)
AT (1)	ATE168267T1 (de)
AU (1)	AU673555B2 (de)
CA (1)	CA2112824A1 (de)
DE (1)	DE69319710T2 (de)
DK (1)	DK0606012T3 (de)
ES (1)	ES2119871T3 (de)
GB (1)	GB9300125D0 (de)
MY (1)	MY110765A (de)
NO (1)	NO940035D0 (de)
NZ (1)	NZ250583A (de)
RU (1)	RU2142468C1 (de)
ZA (1)	ZA9425B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6107499A (en) *	1988-02-26	2000-08-22	Neuromedica, Inc.	Dopamine analog amide
US6576636B2 (en) *	1996-05-22	2003-06-10	Protarga, Inc.	Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en)	1996-05-22	1998-08-18	Neuromedica, Inc.	DHA-pharmaceutical agent conjugates of taxanes
US5977174A (en) *	1997-11-26	1999-11-02	Neuromedica, Inc.	Cholinergic compositions and uses thereof
US6197764B1 (en)	1997-11-26	2001-03-06	Protarga, Inc.	Clozapine compositions and uses thereof
US6153653A (en) *	1997-11-26	2000-11-28	Protarga, Inc.	Choline compositions and uses thereof
US5955459A (en) *	1997-11-26	1999-09-21	Neuromedica, Inc.	Fatty acid-antipsychotic compositions and uses thereof
US6149964A (en) *	1998-05-21	2000-11-21	Beech-Nut Nutrition Corporation	Egg yolk-containing baby food compositions and methods therefor
US6579551B1 (en)	1998-05-21	2003-06-17	Beech-Nut Nutrition Corporation	Baby-food compositions containing egg yolk and methods therefor
US7141266B2 (en) *	1998-05-21	2006-11-28	Beech-Nut Nutrition Corporation	Baby-food compositions enhancing visual acuity and methods therefor
US7413759B2 (en) *	1998-05-21	2008-08-19	Beech-Nut Nutrition Corporation	Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US5892068A (en) *	1998-08-25	1999-04-06	Mcneil-Ppc, Inc.	Preparation of sterol and stanol-esters
NZ333817A (en) *	1998-08-25	2000-09-29	Mcneil Ppc Inc	Process for preparing stanol/sterol fatty acid esters such as beta sitosterol fatty acid esters, useful in reducing cholesterol levels
GB9901809D0 (en)	1999-01-27	1999-03-17	Scarista Limited	Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
AU2006201772B2 (en) *	1999-01-27	2010-02-04	Amarin Neuroscience Limited	Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
US7235583B1 (en)	1999-03-09	2007-06-26	Luitpold Pharmaceuticals, Inc.,	Fatty acid-anticancer conjugates and uses thereof
JP2000355538A (ja) *	1999-04-15	2000-12-26	Kanegafuchi Chem Ind Co Ltd	ペルオキシゾーム活性化剤応答性受容体アゴニスト
EP1175901B1 (de) *	1999-04-15	2006-05-31	Kaneka Corporation	Agonisten des peroxisom aktivator-responsiven rezeptors
US6998501B1 (en) *	1999-08-30	2006-02-14	Ocean Nutrition Canada Limited	Nutritional supplement for lowering serum triglyceride and cholesterol levels
WO2001015552A1 (en) *	1999-08-30	2001-03-08	Ocean Nutrition Canada Ltd.	A nutritional supplement for lowering serum triglyceride and cholesterol levels
US20030206958A1 (en) *	2000-12-22	2003-11-06	Cattaneo Maurizio V.	Chitosan biopolymer for the topical delivery of active agents
ATE384518T1 (de) *	2000-01-31	2008-02-15	Haerting S A	Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
KR20010091499A (ko) *	2000-03-16	2001-10-23	김용범	레이저 그래픽 디스플레이 장치
JP4594489B2 (ja) *	2000-03-31	2010-12-08	備前化成株式会社	特異的殺癌細胞剤及びこれを配合してなる組成物
US8552054B2 (en)	2001-03-23	2013-10-08	Luitpold Pharmaceuticals, Inc.	Fatty amine drug conjugates
JP4634694B2 (ja) *	2001-03-23	2011-02-16	ルイトポルド・ファーマシューティカルズ・インコーポレーテッド	脂肪アルコール薬物複合体
JP2003048831A (ja) *	2001-08-02	2003-02-21	Suntory Ltd	脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
DE10154221A1 (de) *	2001-11-07	2003-05-15	Max Delbrueck Centrum	Mittel zur Behandlung von Läsionen des Nervensystems
EP1587377A2 (de) *	2003-01-31	2005-10-26	The Procter & Gamble Company	Mittel zur verbesserung deserscheinungsbilds von säugetier-keratingewebe
US20050123500A1 (en) *	2003-01-31	2005-06-09	The Procter & Gamble Company	Means for improving the appearance of mammalian hair and nails
WO2004089969A2 (en) *	2003-04-02	2004-10-21	The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services	Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
WO2004112777A1 (ja) *	2003-06-20	2004-12-29	Mochida Pharmaceutical Co., Ltd.	下肢静脈瘤予防・治療用組成物
CA2436650A1 (en) *	2003-08-06	2005-02-06	Naturia Inc.	Conjugated linolenic acid (clnatm) compositions: synthesis, purification and uses
EP1742612A2 (de) *	2004-05-06	2007-01-17	Ivrea Pharmaceuticals, Inc.	Partikel zur wirkstofffreisetzung
US20060141046A1 (en) *	2004-05-06	2006-06-29	Ivrea Pharmaceuticals, Inc.	Particles for the delivery of active agents
RU2444356C2 (ru) *	2005-07-08	2012-03-10	Мартек Байосайенсиз Корпорейшн	Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией
US20080110624A1 (en) *	2005-07-15	2008-05-15	Halliburton Energy Services, Inc.	Methods for controlling water and particulate production in subterranean wells
ITMI20052377A1 (it) *	2005-12-13	2007-06-14	Anna Petroni	Medicamento a base di monoestere di steroidi con acidi grassi a catena lunga
FR2902659A1 (fr) *	2006-06-23	2007-12-28	Pierre Fabre Medicament Sa	Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires
EP4137128A1 (de)	2008-09-02	2023-02-22	Amarin Pharmaceuticals Ireland Limited	Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
ES2768091T3 (es)	2009-02-10	2020-06-19	Amarin Pharmaceuticals Ie Ltd	Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
NZ720946A (en)	2009-04-29	2017-09-29	Amarin Pharmaceuticals Ie Ltd	Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX350088B (es)	2009-04-29	2017-08-25	Amarin Pharma Inc	Composicion farmaceutica estable y metodos de uso de la misma.
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en)	2009-09-23	2011-03-24	Amarin Pharma, Inc.	Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
CN102656153B (zh) *	2009-10-29	2015-02-18	延世大学校产学协力团	新型血管渗漏阻断剂
NZ712068A (en)	2010-11-29	2017-03-31	Amarin Pharmaceuticals Ie Ltd	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en)	2010-11-29	2023-08-01	Amarin Pharmaceuticals Ireland Limited	Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en)	2011-11-07	2022-04-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
US20130131170A1 (en)	2011-11-07	2013-05-23	Amarin Pharmaceuticals Ireland Limited	Methods of treating hypertriglyceridemia
ES2891473T3 (es)	2012-01-06	2022-01-28	Amarin Pharmaceuticals Ie Ltd	Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
CA3067012C (en)	2012-06-29	2021-10-05	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US9717741B2 (en)	2012-10-11	2017-08-01	Anaplasi Pharmaceuticals Llc	Method and compositions for treating psoriasis
CA2886024C (en) *	2012-10-11	2019-10-29	Anaplasi Pharmaceuticals Llc	Method and compositions for treating psoriasis
WO2014074552A2 (en)	2012-11-06	2014-05-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en)	2012-12-31	2014-07-03	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en)	2012-12-31	2017-11-14	A,arin Pharmaceuticals Ireland Limited	Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en)	2013-02-06	2016-09-27	Amarin Pharmaceuticals Ireland Limited	Methods of reducing apolipoprotein C-III
US9624492B2 (en)	2013-02-13	2017-04-18	Amarin Pharmaceuticals Ireland Limited	Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en)	2013-02-19	2017-05-30	The Regents Of The University Of Colorado	Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en)	2013-03-14	2016-03-15	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en)	2013-03-15	2014-09-18	Amarin Pharmaceuticals Ireland Limited	Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en)	2013-06-06	2021-04-06	Amarin Pharmaceuticals Ireland Limited	Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en)	2013-09-04	2015-03-05	Amarin Pharmaceuticals Ireland Limited	Methods of treating or preventing prostate cancer
US9585859B2 (en)	2013-10-10	2017-03-07	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en)	2014-06-11	2020-02-18	Amarin Pharmaceuticals Ireland Limited	Methods of reducing RLP-C
US10172818B2 (en)	2014-06-16	2019-01-08	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en)	2016-03-15	2019-09-10	Amarin Pharmaceuticals Ireland Limited	Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
JP6224203B2 (ja) *	2016-12-08	2017-11-01	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するための組成物
WO2018213663A1 (en)	2017-05-19	2018-11-22	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP6491293B2 (ja) *	2017-10-04	2019-03-27	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するためのエアロゾル、ムース、又はフォームの組成物
US11058661B2 (en)	2018-03-02	2021-07-13	Amarin Pharmaceuticals Ireland Limited	Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
JP6728425B2 (ja) *	2019-02-28	2020-07-22	アナプラシファーマシューティカルズエルエルシー	乾癬を治療するためのクリーム、ローション、又はゲルの組成物
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4442037A (en) *	1981-03-13	1984-04-10	Yoshio Arakawa	Water-soluble cholesterol derivative
GB8524275D0 (en) *	1985-10-02	1985-11-06	Efamol Ltd	Pharmaceutical & dietary compositions
SU1456442A1 (ru) *	1987-04-03	1989-02-07	Житомирский Государственный Педагогический Институт Им.И.Франко	(Холестерилоксикарбонилметил)трифенилфосфонийхлорид в качестве полупродукта в синтезе холестериловых эфиров непредельных карбоновых кислот

1993
- 1993-01-06 GB GB939300125A patent/GB9300125D0/en active Pending
- 1993-12-23 NZ NZ250583A patent/NZ250583A/xx unknown
- 1993-12-29 ES ES93310599T patent/ES2119871T3/es not_active Expired - Lifetime
- 1993-12-29 EP EP93310599A patent/EP0606012B1/de not_active Expired - Lifetime
- 1993-12-29 AT AT93310599T patent/ATE168267T1/de not_active IP Right Cessation
- 1993-12-29 DE DE69319710T patent/DE69319710T2/de not_active Expired - Fee Related
- 1993-12-29 DK DK93310599T patent/DK0606012T3/da active
- 1993-12-30 AU AU52763/93A patent/AU673555B2/en not_active Ceased
1994
- 1994-01-04 ZA ZA9425A patent/ZA9425B/xx unknown
- 1994-01-04 MY MYPI94000009A patent/MY110765A/en unknown
- 1994-01-05 RU RU94000061A patent/RU2142468C1/ru active
- 1994-01-05 CA CA002112824A patent/CA2112824A1/en not_active Abandoned
- 1994-01-05 NO NO940035A patent/NO940035D0/no unknown
- 1994-01-06 US US08/178,553 patent/US5604216A/en not_active Expired - Fee Related
- 1994-01-06 KR KR1019940000159A patent/KR940018088A/ko not_active Ceased
- 1994-01-06 JP JP6000338A patent/JPH06234644A/ja active Pending
- 1994-01-06 CN CN94100242A patent/CN1096197A/zh active Pending

Also Published As

Publication number	Publication date
GB9300125D0 (en)	1993-03-03
MY110765A (en)	1999-03-31
AU673555B2 (en)	1996-11-14
US5604216A (en)	1997-02-18
ES2119871T3 (es)	1998-10-16
EP0606012B1 (de)	1998-07-15
DE69319710T2 (de)	1999-03-11
NO940035L (de)	1994-07-07
RU2142468C1 (ru)	1999-12-10
AU5276393A (en)	1994-07-14
NZ250583A (en)	1997-08-22
CA2112824A1 (en)	1994-07-07
KR940018088A (ko)	1994-08-16
ATE168267T1 (de)	1998-08-15
DK0606012T3 (da)	1999-04-19
EP0606012A1 (de)	1994-07-13
JPH06234644A (ja)	1994-08-23
DE69319710D1 (de)	1998-08-20
ZA9425B (en)	1994-08-19
CN1096197A (zh)	1994-12-14

Publication	Publication Date	Title
NO940035L (de)	1994-07-07
RU94000061A (ru)	1995-08-27	Эфиры холестерина и ненасыщенных жирных кислот, способ лечения и фармацевтическая или косметическая композиция
AU2080988A (en)	1989-01-30	Esters of 13-trans-retinoic acid
AU7053494A (en)	1995-01-03	Method of treating coronary vascular disease using docosahexaenoic acid
FI940874A0 (fi)	1994-02-24	Menetelmä maitohapon ja maitohappoestereiden valmistamiseksi
NO950784D0 (no)	1995-02-28	Fettsyrederivater
AU660223B2 (en)	1995-06-15	Fatty acid treatment
EP0596838A3 (en)	1994-06-01	Esters of l-carnitine and alkanoyl l-carnitines with glycolic acid or esters thereof and pharmaceutical compositions containing same for treating dermatoses.
KR0148213B1 (en)	1998-08-17	Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
NO885601D0 (no)	1988-12-16	Eventuelt kvataererte fettsyreestre av oxalkylerte alkyl-alkylendiaminer.
AU1438295A (en)	1995-07-03	Method for treatment of papulo-pustules and comedones of the skin
WO1995015161A3 (de)	1995-06-29	Arzneimittel zur behandlung der herzinsuffizienz
NO892505L (no)	1989-12-21	Behandling av vandige dispersjoner.
FI954138L (fi)	1995-09-04	Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
AU6608994A (en)	1995-01-12	Compositions for the treatment of inflammatory proliferative skin disease and their use
DE3773059D1 (de)	1991-10-24	Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien.
AU2907884A (en)	1984-12-13	6-(aminomethyl) penicillanic acid 1,1-dioxide esters
IE811612L (en)	1982-01-19	Thiazoles
ES2191671T3 (es)	2003-09-16	Esteres de 1,4-dihidropiridina 4-fenil-3-sustituidos.
RU93056862A (ru)	1996-10-10	Способ предотвращения рестеноза или снижения его степени
AU7885998A (en)	1998-10-08	Use of cis- or transurocamic acid for the treatment of photodermatoses and immunogenic skin diseases
CA2062422A1 (en)	1992-09-09	Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
NO890312L (no)	1989-01-25	Fremgangsmaate for behandling av flytende metaller.